JP2022062153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022062153A5 JP2022062153A5 JP2022014339A JP2022014339A JP2022062153A5 JP 2022062153 A5 JP2022062153 A5 JP 2022062153A5 JP 2022014339 A JP2022014339 A JP 2022014339A JP 2022014339 A JP2022014339 A JP 2022014339A JP 2022062153 A5 JP2022062153 A5 JP 2022062153A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- dulaglutide
- composition according
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229960005175 dulaglutide Drugs 0.000 claims 6
- 108010005794 dulaglutide Proteins 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000002641 glycemic effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 229940038773 trisodium citrate Drugs 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024021637A JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| US62/589,244 | 2017-11-21 | ||
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
| JP2020525974A JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Division JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021637A Division JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022062153A JP2022062153A (ja) | 2022-04-19 |
| JP2022062153A5 true JP2022062153A5 (enExample) | 2023-02-10 |
Family
ID=64572530
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2022014339A Pending JP2022062153A (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11576950B2 (enExample) |
| EP (1) | EP3713593A2 (enExample) |
| JP (3) | JP7221956B2 (enExample) |
| KR (2) | KR20220146656A (enExample) |
| CN (2) | CN120478602A (enExample) |
| AU (2) | AU2018372709B2 (enExample) |
| BR (1) | BR112020007817A2 (enExample) |
| CA (1) | CA3082625A1 (enExample) |
| CL (1) | CL2020001252A1 (enExample) |
| CR (1) | CR20200202A (enExample) |
| DO (1) | DOP2020000104A (enExample) |
| EA (1) | EA202090971A1 (enExample) |
| EC (1) | ECSP20026436A (enExample) |
| IL (1) | IL274563B2 (enExample) |
| JO (1) | JOP20200126A1 (enExample) |
| MA (1) | MA50798A (enExample) |
| MX (1) | MX2020005231A (enExample) |
| PE (1) | PE20200847A1 (enExample) |
| PH (1) | PH12020550795A1 (enExample) |
| SG (1) | SG11202003687RA (enExample) |
| UA (1) | UA127588C2 (enExample) |
| WO (1) | WO2019103875A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7728176B2 (ja) * | 2019-03-15 | 2025-08-22 | イーライ リリー アンド カンパニー | 保存製剤 |
| MX2022009383A (es) * | 2020-01-30 | 2022-11-07 | Lilly Co Eli | Usos terapéuticos de dulaglutida. |
| EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| EA011166B1 (ru) | 2004-12-22 | 2009-02-27 | Эли Лилли Энд Компани | Композиции слитых белков-аналогов glp-1 |
| EA201070121A1 (ru) | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| JP7191043B2 (ja) | 2017-06-01 | 2022-12-16 | イーライ リリー アンド カンパニー | 慢性腎疾患の治療のためのデュラグルチド |
-
2018
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 CA CA3082625A patent/CA3082625A1/en active Pending
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 JO JOP/2020/0126A patent/JOP20200126A1/ar unknown
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP2022062153A/ja active Pending
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022062153A5 (enExample) | ||
| JP2018111728A5 (enExample) | ||
| JP2018138578A5 (enExample) | ||
| ME01337B (me) | Tečni preparat fsh | |
| KR101420315B1 (ko) | 약학적 액제 조성물 | |
| JP2011515404A5 (enExample) | ||
| RU2366450C1 (ru) | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций | |
| CN111093625A (zh) | 达托霉素制剂 | |
| JP2021502379A5 (enExample) | ||
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| EP0630649A1 (en) | Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid | |
| HRP20241022T1 (hr) | Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos) | |
| JP2018521139A (ja) | 急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物 | |
| RU2417083C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний | |
| US12409156B2 (en) | Stable aqueous hydroxycarbamide solution | |
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| JP2017528526A (ja) | α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤 | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| US20240148707A1 (en) | Modulation of drug-drug interactions of vadadustat | |
| JP2025535828A (ja) | エキノカンジン類似体の医薬組成物及びその調製方法 | |
| JP2007506683A (ja) | ヒト成長ホルモン剤およびその調整方法と使用方法 | |
| RU2751351C2 (ru) | Пероральный препарат ибупрофена | |
| JP2009507850A5 (enExample) | ||
| CN103520515A (zh) | 鼓槌石斛提取物及其医药用途 | |
| CN116077650A (zh) | 一种稳定的新冠中和抗体的药物组合物及其应用 |